NEVVI Medicare utilization intelligence

← back

Provider profile

SCHATTNER, GAIL M.D.

Pulmonary Disease · NPI 1710996764 · NEW YORK, NY

1
Groups
24
Codes · 2024
46,532
Disclosed services

SCHATTNER, GAIL is a Pulmonary Disease in NEW YORK, NY, a member of 1 medical group, who billed 24 distinct codes to Medicare Part B in 2024.

Groups: NEW YORK UNIVERSITY (NEW YORK, NY)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

46,532
disclosed services
24
codes billed to Medicare Part B
Prior year · CY2023 40,923 disclosed services

This provider's disclosed Medicare payments across all codes were premium in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J2182 Injection, mepolizumab, 1 mg premiumpremium premiumpremium
J2356 Injection, tezepelumab-ekko, 1 mg premiumpremium premiumpremium
J0517 Injection, benralizumab, 1 mg premiumpremium premiumpremium
J7613 Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg premiumpremium premiumpremium
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more premiumpremium premiumpremium
94060 Test to measure expiratory airflow and volume changes before and after medication administration premiumpremium premiumpremium
96372 Injection of drug or substance under skin or into muscle premiumpremium premiumpremium
94726 Test to determine lung volumes using sensors premiumpremium premiumpremium
94729 Test to examine how well the lungs exchange gases premiumpremium premiumpremium
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more premiumpremium premiumpremium
36415 Insertion of needle into vein for collection of blood sample premiumpremium premiumpremium
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more premiumpremium premiumpremium
J7612 Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 0.5 mg premiumpremium premiumpremium
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's premiumpremium premiumpremium
94010 Test to measure expiratory airflow and volume premiumpremium premiumpremium
94618 Test for exercise-induced lung stress premiumpremium premiumpremium
95012 Test to measure the level of nitric oxide gas premiumpremium premiumpremium
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more premiumpremium premiumpremium
G0008 Administration of influenza virus vaccine premiumpremium premiumpremium
90662 Influenza vaccine split virus, preservative free premiumpremium premiumpremium
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more premiumpremium premiumpremium
J7614 Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg premiumpremium premiumpremium
90677 Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use premiumpremium premiumpremium
G0009 Administration of pneumococcal vaccine premiumpremium premiumpremium

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.